NEUROONE MEDICAL TECHNOLOGIES Corp
For the period ended Sep 30, 2024. Filed Dec 17, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 17, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: December 17, 2024 | NEUROONE MEDICAL TECHNOLOGIES CORPORATION | |
|---|---|---|
| By: | /s/ DAVID ROSA | |
| David Rosa | ||
| Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| SIGNATURE | TITLE | DATE |
|---|---|---|
| /s/ DAVID ROSA | Chief Executive Officer and Director | December 17, 2024 |
| David Rosa | (Principal Executive Officer) | |
| /s/ RONALD MCCLURG | Chief Financial Officer | December 17, 2024 |
| Ronald McClurg | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ PAUL BUCKMAN | Chairman of the Board of Directors | December 17, 2024 |
| Paul Buckman | ||
| /s/ EDWARD ANDRLE | Member of the Board of Directors | December 17, 2024 |
| Edward Andrle | ||
| /s/ JEFFREY MATHIESEN | Member of the Board of Directors | December 17, 2024 |
| Jeffrey Mathiesen | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.